Meloxicam: Nursing Drug Guide, GI Bleeding & Hold Rules

Meloxicam is marketed as Mobic, Vivlodex, and Qmiiz ODT (orally disintegrating tablet) among other brands. Prescription tablets are typically 7.5 mg and 15 mg once daily. Patients may say “Mobic” while the MAR lists generic meloxicam—confirm strength and that no second NSAID is taken the same day.

Do not confuse meloxicam with acetaminophen (different toxicity profile) or with other NSAIDs (ibuprofen, naproxen, diclofenac, celecoxib) when reconciling therapy. Duplicate NSAID exposure dramatically increases GI bleeding and renal risk per NSAID class labeling.

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) in the oxicam class that inhibits cyclooxygenase, reducing prostaglandin-mediated pain and inflammation. Meloxicam tablets are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis per labeling. It is not a general multipurpose PRN analgesic on most inpatient orders—verify the indication matches OA or RA and that no other NSAID is scheduled or taken at home the same day.

↔On a small screen, swipe or scroll sideways to see the full table.

Meloxicam inhibits cyclooxygenase, decreasing prostaglandin synthesis involved in pain and inflammation. Like other NSAIDs, it carries a boxed warning for serious cardiovascular thrombotic events and serious GI bleeding. After oral dosing, mean peak concentrations occur in about four to five hours under fasted conditions, with an elimination half-life of approximately 20 hours—supporting once-daily dosing. NSAIDs may reduce renal perfusion in patients who depend on prostaglandins—especially when combined with furosemide, thiazides, or ACE inhibitors such as enalapril.

Use the lowest effective dose for the shortest duration consistent with treatment goals. Verify indication (OA or RA), hepatic and renal function, concurrent anticoagulant or diuretic therapy, and all other NSAID sources before administration. Do not exceed 15 mg total daily oral dose in adults per labeling.

Administration tip: Meloxicam may be taken without regard to timing of meals per labeling. If GI upset occurs, taking with food may help tolerance—report persistent dyspepsia or bleeding symptoms.

Missed dose: If a once-daily dose is missed, give when remembered the same day if appropriate per prescriber—do not double the next dose to catch up. Do not exceed 15 mg in 24 hours.

↔On a small screen, swipe or scroll sideways to see the full table.

Pretreatment checks

• Perform medication reconciliation—screen for duplicate NSAIDs, aspirin, anticoagulants, ACE inhibitors, ARBs, and diuretics
• Review allergy history: meloxicam, aspirin/NSAID reactions, aspirin-sensitive asthma, prior serious NSAID skin reactions
• Assess cardiovascular history, blood pressure, edema, renal function (BUN/creatinine), and prior GI bleeding or peptic ulcer disease
• Confirm surgical plan—hold per protocol before CABG; NSAIDs are contraindicated for CABG pain

Contraindications

• Known hypersensitivity to meloxicam (e.g., anaphylactoid reactions, serious skin reactions) or any formulation excipient
• History of asthma, urticaria, or allergic-type reactions after aspirin or other NSAIDs
• Peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery
• Prior serious skin reactions to NSAIDs (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) per labeling warnings

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Oral tablets: 7.5 mg and 15 mg tablets per labeling. Swallow with water; may be taken without regard to meals. Confirm only one NSAID is active—patients may not realize Mobic is an NSAID because it is dosed once daily.

Home medication review: Ask about Mobic, naproxen, ibuprofen, and combination cold products—always reconcile duplicate NSAIDs at admission and discharge.

• Confirm home OTC NSAIDs, low-dose aspirin, and herbal antiplatelet supplements are documented after reconciliation
• Document indication, dose, route, time, and pain score before and after PRN doses
• Ensure fall-risk precautions in older adults with orthostatic symptoms, especially when bleeding or anemia develops

• Improved pain score or joint stiffness with functional mobility gains in arthritis
• Reduced swelling and tenderness on joint exam when inflammation is present
• No new GI bleeding, blood pressure elevation, edema, or renal function decline while therapy continues

Hold meloxicam and escalate immediately when serious NSAID complications are suspected.

• Black stool, hematemesis, coffee-ground emesis, or severe abdominal pain suggesting GI bleeding
• Chest pain, sudden weakness, facial droop, slurred speech, or other stroke or MI symptoms
• New or worsening dyspnea, rapid weight gain, or dependent edema in patients with heart failure
• Decreased urine output, rising creatinine, or hyperkalemia suggesting acute kidney injury
• Urticaria, facial swelling, wheezing, or anaphylaxis after a dose
• Jaundice, dark urine, or persistent nausea with rising AST/ALT on liver function tests

↔On a small screen, swipe or scroll sideways to see the full table.

There is limited experience with meloxicam overdose; published cases ingesting 6 to 11 times the highest recommended dose recovered with supportive care per labeling. Symptoms following acute NSAID overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Severe poisoning may result in hypertension, acute renal failure, hepatic dysfunction, respiratory depression, coma, convulsions, cardiovascular collapse, and cardiac arrest. Anaphylactoid reactions may occur.

Management

• No specific antidote—manage with symptomatic and supportive care per NSAID overdose guidance
• Consider activated charcoal if presentation is 1–2 hours after ingestion; repeated doses may be used in substantial overdose per labeling
• Cholestyramine 4 g three times daily accelerated meloxicam clearance in a clinical study—may be useful after overdose per labeling
• Forced diuresis, urine alkalinization, hemodialysis, or hemoperfusion are unlikely to be useful due to high protein binding
• Monitor airway, GI bleeding, renal function, and hemodynamics; contact local poison control or medical toxicology per facility protocol

• Meloxicam vs metolazone—sound-alike diuretic; verify generic name on MAR and read-back orders
• Meloxicam vs methotrexate—both used in rheumatology; confirm drug name, day of therapy, and NSAID–methotrexate interaction screening
• Strength errors—confirm 7.5 mg vs 15 mg tablets; do not give two tablets thinking “low dose” without order clarification
• Duplicate NSAID therapy—once-daily meloxicam plus home naproxen or ibuprofen is a common error because dosing schedules differ
• Mobic brand confusion—patients may not list Mobic as an NSAID; always ask brand and generic names on reconciliation

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Pain and function using structured pain assessment and mobility goals
• GI status—stool color, hemoglobin trend, and symptoms of bleeding or ulcer
• Blood pressure, weight, edema, and heart failure symptoms
• Renal function and electrolytes on BMP when diuretics, ACE inhibitors, or ARBs are co-administered
• INR and bleeding signs when anticoagulants are used
• LFTs when hepatic risk factors or symptoms are present

Document

• Dose, route, time, indication, and pain score response for PRN doses
• Allergy verification (NSAID, aspirin-sensitive asthma, prior serious skin reaction)
• Patient education on bleeding, cardiovascular symptoms, and when to seek urgent care
• Hold parameters communicated to patient and on the MAR per institutional policy

• Take meloxicam once daily as prescribed—do not combine with naproxen, ibuprofen, diclofenac, or other NSAIDs unless your prescriber directs you; Mobic is an NSAID even with once-daily dosing
• Report black or bloody stools, vomiting blood, severe stomach pain, chest pain, shortness of breath, sudden weakness, facial swelling, or rash immediately
• NSAIDs can raise blood pressure and cause swelling—report rapid weight gain or ankle swelling
• Tell all clinicians you take meloxicam before surgery, dental procedures, or new prescriptions
• Do not exceed 15 mg in one day; if pain is not controlled, contact your prescriber rather than adding OTC NSAIDs
• Pregnancy planning: discuss risks with your prescriber—avoid late-pregnancy use per labeling

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Practice NCLEX-style clinical judgment practice for meloxicam using a tabbed inpatient case (MAR, labs, I&O, nursing notes), then priority action, cue recognition, trend interpretation, ordered escalation steps, documentation cloze, and matrix urgency sorting—recognise duplicate NSAID risk → analyse renal/GI trends → prioritise holds → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.